A detailed history of Barclays PLC transactions in Axogen, Inc. stock. As of the latest transaction made, Barclays PLC holds 32,854 shares of AXGN stock, worth $453,056. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,854
Previous 42,025 21.82%
Holding current value
$453,056
Previous $339,000 29.5%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.67 - $8.06 $51,999 - $73,918
-9,171 Reduced 21.82%
32,854 $239,000
Q1 2024

May 15, 2024

SELL
$6.63 - $10.69 $184,658 - $297,737
-27,852 Reduced 39.86%
42,025 $339,000
Q4 2023

Feb 15, 2024

BUY
$3.61 - $7.76 $148,811 - $319,882
41,222 Added 143.86%
69,877 $477,000
Q3 2023

Nov 07, 2023

BUY
$4.68 - $9.26 $20,531 - $40,623
4,387 Added 18.08%
28,655 $142,000
Q2 2023

Aug 03, 2023

SELL
$8.5 - $10.38 $43,715 - $53,384
-5,143 Reduced 17.49%
24,268 $222,000
Q1 2023

May 04, 2023

BUY
$7.53 - $10.95 $72,626 - $105,612
9,645 Added 48.8%
29,411 $278,000
Q4 2022

Feb 13, 2023

BUY
$9.44 - $13.09 $86,536 - $119,996
9,167 Added 86.49%
19,766 $197,000
Q3 2022

Nov 03, 2022

SELL
$8.14 - $12.25 $2,572 - $3,871
-316 Reduced 2.9%
10,599 $126,000
Q2 2022

Aug 12, 2022

SELL
$6.99 - $10.0 $30,930 - $44,250
-4,425 Reduced 28.85%
10,915 $90,000
Q1 2022

May 16, 2022

SELL
$7.26 - $10.7 $290,821 - $428,620
-40,058 Reduced 72.31%
15,340 $122,000
Q4 2021

Feb 14, 2022

BUY
$8.8 - $16.0 $249,128 - $452,960
28,310 Added 104.51%
55,398 $519,000
Q3 2021

Nov 09, 2021

BUY
$15.23 - $21.72 $165,108 - $235,466
10,841 Added 66.73%
27,088 $429,000
Q2 2021

Aug 13, 2021

SELL
$17.8 - $23.5 $501,212 - $661,713
-28,158 Reduced 63.41%
16,247 $352,000
Q1 2021

May 13, 2021

BUY
$17.18 - $22.6 $182,296 - $239,808
10,611 Added 31.4%
44,405 $900,000
Q4 2020

Feb 11, 2021

SELL
$11.5 - $17.96 $56,821 - $88,740
-4,941 Reduced 12.76%
33,794 $605,000
Q3 2020

Nov 12, 2020

SELL
$10.62 - $13.12 $90,567 - $111,887
-8,528 Reduced 18.04%
38,735 $450,000
Q2 2020

Aug 12, 2020

BUY
$7.35 - $10.81 $184,301 - $271,060
25,075 Added 113.01%
47,263 $437,000
Q1 2020

May 13, 2020

SELL
$8.38 - $17.34 $172,292 - $356,510
-20,560 Reduced 48.1%
22,188 $230,000
Q4 2019

Feb 10, 2020

BUY
$11.18 - $18.6 $172,731 - $287,370
15,450 Added 56.6%
42,748 $766,000
Q3 2019

Nov 14, 2019

SELL
$12.09 - $20.46 $193,210 - $326,971
-15,981 Reduced 36.93%
27,298 $341,000
Q2 2019

Aug 14, 2019

SELL
$18.5 - $25.47 $3.19 Million - $4.4 Million
-172,624 Reduced 79.95%
43,279 $857,000
Q1 2019

May 15, 2019

BUY
$14.62 - $22.13 $3.02 Million - $4.58 Million
206,737 Added 2255.48%
215,903 $4.55 Million
Q4 2018

Feb 14, 2019

SELL
$17.09 - $38.25 $274,704 - $614,830
-16,074 Reduced 63.68%
9,166 $187,000
Q3 2018

Nov 14, 2018

BUY
$34.05 - $55.9 $705,890 - $1.16 Million
20,731 Added 459.77%
25,240 $930,000
Q2 2018

Aug 14, 2018

SELL
$36.15 - $52.5 $113,908 - $165,427
-3,151 Reduced 41.14%
4,509 $227,000
Q1 2018

May 15, 2018

BUY
$24.4 - $40.25 $79,763 - $131,577
3,269 Added 74.45%
7,660 $280,000
Q4 2017

Feb 14, 2018

BUY
$18.5 - $28.6 $69,541 - $107,507
3,759 Added 594.78%
4,391 $125,000
Q3 2017

Nov 14, 2017

BUY
$14.65 - $19.35 $9,258 - $12,229
632
632 $12,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $583M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.